

## COMMERCIALIZATION MODELS OF POTENTIAL GLYCOPRODUCTS

Károly Ágoston\*, Inge Lundt, Joachim Thiem, Arnold Stütz, István Bajza, Lars Kröger,  
Gyula Dékány

Glycom A/S; Building 201, Danish Technical University, Lyngby, 2800 Kgs, Denmark;  
[ka@glycom.dk](mailto:ka@glycom.dk)

Establishment of Glycom A/S followed by commercialization efforts of several potential carbohydrate type products will be presented. IP platform required for efficient business development will be outlined. The following projects and their commercialization activities will be discussed in details:

### 1,5-Anhydrofructose

Scientific background, biological activities, potential application fields, novel synthetic technologies suitable for the production of 1,5 anhydrofructose and commercialization actions will be described.

### Glycomatrix

A novel concept for the generation of diversities in the synthesis of complex oligosaccharides via the use of novel glycomatrices will be introduced

### Selective human insulin glycosylation and cell surface engineering via novel ligation technologies

Novel glycoligation methodologies, their applications in therapeutic protein modification by using a human insulin model will be explored. Furthermore, the utility of a novel glycoligation in cell surface modification within immunology will be discussed by delivering carbohydrate epitopes to cells.

### Technology development of human milk oligosaccharides

Glycom's outstanding technology success in manufacturing of human milk oligosaccharides will be presented. Scientific breakthroughs, kg-laboratory studies, pilot plant and industrial productions of key building blocks and selected human milk oligosaccharides will be outlined.